NCT07937696
A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Participant-level response rate
Timeframe: Baseline to week 16
Secondary (5)
Change in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm, regardless of mismatch repair (MMR) status
Development of new colorectal lesions
Change in the size of colorectal lesions that are < 5 mm and > 15 mm in diameter
Incidence and severity of adverse events
Immunogenicity of Nous-209
Arms and interventions
Prevention (Nous-209)Experimental
Patients receive GAd20-209-FSP IM at week 0 (day 1) followed by MVA-209-FSP IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.
Biologicals: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Procedures: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Sigmoidoscopy
Sites
5 sites in 1 country